NASDAQ:MRSN

Mersana Therapeutics Competitors

$17.14
+0.98 (+6.06 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.32
Now: $17.14
$17.86
50-Day Range
$15.31
MA: $17.45
$19.78
52-Week Range
$7.66
Now: $17.14
$29.09
Volume681,219 shs
Average Volume1.05 million shs
Market Capitalization$1.18 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.54

Competitors

Mersana Therapeutics (NASDAQ:MRSN) Vs. BHVN, AVIR, SAGE, HCM, ARNA, and EBS

Should you be buying MRSN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Mersana Therapeutics, including Biohaven Pharmaceutical (BHVN), Atea Pharmaceuticals (AVIR), Sage Therapeutics (SAGE), Hutchison China MediTech (HCM), Arena Pharmaceuticals (ARNA), and Emergent BioSolutions (EBS).

Biohaven Pharmaceutical (NYSE:BHVN) and Mersana Therapeutics (NASDAQ:MRSN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Earnings and Valuation

This table compares Biohaven Pharmaceutical and Mersana Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-6.86
Mersana Therapeutics$42.12 million28.10$-28,210,000.00($0.65)-26.37

Mersana Therapeutics has higher revenue and earnings than Biohaven Pharmaceutical. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Biohaven Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Biohaven Pharmaceutical has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 2.54, meaning that its share price is 154% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Biohaven Pharmaceutical and Mersana Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biohaven Pharmaceutical021002.83
Mersana Therapeutics02502.71

Biohaven Pharmaceutical presently has a consensus price target of $96.4545, indicating a potential upside of 28.95%. Mersana Therapeutics has a consensus price target of $26.1667, indicating a potential upside of 52.66%. Given Mersana Therapeutics' higher probable upside, analysts plainly believe Mersana Therapeutics is more favorable than Biohaven Pharmaceutical.

Institutional and Insider Ownership

99.4% of Biohaven Pharmaceutical shares are owned by institutional investors. 19.1% of Biohaven Pharmaceutical shares are owned by company insiders. Comparatively, 5.3% of Mersana Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Biohaven Pharmaceutical and Mersana Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biohaven PharmaceuticalN/A-1,091.41%-120.85%
Mersana Therapeutics-8,772.91%-45.16%-37.53%

Summary

Mersana Therapeutics beats Biohaven Pharmaceutical on 7 of the 13 factors compared between the two stocks.

Atea Pharmaceuticals (NASDAQ:AVIR) and Mersana Therapeutics (NASDAQ:MRSN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Earnings & Valuation

This table compares Atea Pharmaceuticals and Mersana Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atea PharmaceuticalsN/AN/AN/AN/AN/A
Mersana Therapeutics$42.12 million28.10$-28,210,000.00($0.65)-26.37

Atea Pharmaceuticals has higher earnings, but lower revenue than Mersana Therapeutics.

Analyst Recommendations

This is a summary of recent ratings and price targets for Atea Pharmaceuticals and Mersana Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atea Pharmaceuticals00403.00
Mersana Therapeutics02502.71

Atea Pharmaceuticals currently has a consensus price target of $69.3333, indicating a potential upside of 27.03%. Mersana Therapeutics has a consensus price target of $26.1667, indicating a potential upside of 52.66%. Given Mersana Therapeutics' higher probable upside, analysts clearly believe Mersana Therapeutics is more favorable than Atea Pharmaceuticals.

Profitability

This table compares Atea Pharmaceuticals and Mersana Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atea PharmaceuticalsN/AN/AN/A
Mersana Therapeutics-8,772.91%-45.16%-37.53%

Summary

Atea Pharmaceuticals beats Mersana Therapeutics on 4 of the 7 factors compared between the two stocks.

Sage Therapeutics (NASDAQ:SAGE) and Mersana Therapeutics (NASDAQ:MRSN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Earnings & Valuation

This table compares Sage Therapeutics and Mersana Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sage Therapeutics$6.87 million643.05$-680,240,000.00($13.38)-5.66
Mersana Therapeutics$42.12 million28.10$-28,210,000.00($0.65)-26.37

Mersana Therapeutics has higher revenue and earnings than Sage Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Sage Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 2.54, suggesting that its share price is 154% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Sage Therapeutics and Mersana Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sage Therapeutics08802.50
Mersana Therapeutics02502.71

Sage Therapeutics currently has a consensus price target of $87.0625, indicating a potential upside of 15.06%. Mersana Therapeutics has a consensus price target of $26.1667, indicating a potential upside of 52.66%. Given Mersana Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Mersana Therapeutics is more favorable than Sage Therapeutics.

Profitability

This table compares Sage Therapeutics and Mersana Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sage Therapeutics-7,706.84%-63.81%-56.64%
Mersana Therapeutics-8,772.91%-45.16%-37.53%

Summary

Mersana Therapeutics beats Sage Therapeutics on 8 of the 12 factors compared between the two stocks.

Hutchison China MediTech (NASDAQ:HCM) and Mersana Therapeutics (NASDAQ:MRSN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Institutional & Insider Ownership

33.5% of Hutchison China MediTech shares are owned by institutional investors. 5.3% of Mersana Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for Hutchison China MediTech and Mersana Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hutchison China MediTech00203.00
Mersana Therapeutics02502.71

Hutchison China MediTech currently has a consensus price target of $40.00, indicating a potential upside of 37.03%. Mersana Therapeutics has a consensus price target of $26.1667, indicating a potential upside of 52.66%. Given Mersana Therapeutics' higher probable upside, analysts clearly believe Mersana Therapeutics is more favorable than Hutchison China MediTech.

Profitability

This table compares Hutchison China MediTech and Mersana Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hutchison China MediTechN/AN/AN/A
Mersana Therapeutics-8,772.91%-45.16%-37.53%

Volatility & Risk

Hutchison China MediTech has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 2.54, meaning that its stock price is 154% more volatile than the S&P 500.

Earnings & Valuation

This table compares Hutchison China MediTech and Mersana Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hutchison China MediTech$204.89 million20.74$-106,020,000.00($0.80)-36.49
Mersana Therapeutics$42.12 million28.10$-28,210,000.00($0.65)-26.37

Mersana Therapeutics has lower revenue, but higher earnings than Hutchison China MediTech. Hutchison China MediTech is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Mersana Therapeutics beats Hutchison China MediTech on 8 of the 14 factors compared between the two stocks.

Arena Pharmaceuticals (NASDAQ:ARNA) and Mersana Therapeutics (NASDAQ:MRSN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.

Insider & Institutional Ownership

89.7% of Arena Pharmaceuticals shares are held by institutional investors. 3.1% of Arena Pharmaceuticals shares are held by company insiders. Comparatively, 5.3% of Mersana Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Arena Pharmaceuticals and Mersana Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arena Pharmaceuticals001503.00
Mersana Therapeutics02502.71

Arena Pharmaceuticals currently has a consensus price target of $92.80, indicating a potential upside of 37.20%. Mersana Therapeutics has a consensus price target of $26.1667, indicating a potential upside of 52.66%. Given Mersana Therapeutics' higher probable upside, analysts clearly believe Mersana Therapeutics is more favorable than Arena Pharmaceuticals.

Profitability

This table compares Arena Pharmaceuticals and Mersana Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arena PharmaceuticalsN/A-33.17%-30.41%
Mersana Therapeutics-8,772.91%-45.16%-37.53%

Risk & Volatility

Arena Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 2.54, indicating that its share price is 154% more volatile than the S&P 500.

Valuation & Earnings

This table compares Arena Pharmaceuticals and Mersana Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arena Pharmaceuticals$806.43 million5.06$397.55 million$7.698.80
Mersana Therapeutics$42.12 million28.10$-28,210,000.00($0.65)-26.37

Arena Pharmaceuticals has higher revenue and earnings than Mersana Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Arena Pharmaceuticals beats Mersana Therapeutics on 10 of the 14 factors compared between the two stocks.

Emergent BioSolutions (NYSE:EBS) and Mersana Therapeutics (NASDAQ:MRSN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.

Insider & Institutional Ownership

80.2% of Emergent BioSolutions shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by company insiders. Comparatively, 5.3% of Mersana Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Emergent BioSolutions and Mersana Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emergent BioSolutions12.50%26.68%12.70%
Mersana Therapeutics-8,772.91%-45.16%-37.53%

Valuation & Earnings

This table compares Emergent BioSolutions and Mersana Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emergent BioSolutions$1.11 billion3.59$54.50 million$2.9125.59
Mersana Therapeutics$42.12 million28.10$-28,210,000.00($0.65)-26.37

Emergent BioSolutions has higher revenue and earnings than Mersana Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Emergent BioSolutions and Mersana Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emergent BioSolutions02502.71
Mersana Therapeutics02502.71

Emergent BioSolutions currently has a consensus price target of $113.6667, indicating a potential upside of 52.63%. Mersana Therapeutics has a consensus price target of $26.1667, indicating a potential upside of 52.66%. Given Mersana Therapeutics' higher probable upside, analysts clearly believe Mersana Therapeutics is more favorable than Emergent BioSolutions.

Risk & Volatility

Emergent BioSolutions has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 2.54, indicating that its share price is 154% more volatile than the S&P 500.

Summary

Emergent BioSolutions beats Mersana Therapeutics on 9 of the 12 factors compared between the two stocks.


Mersana Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.80+2.7%$4.64 billionN/A-6.10Analyst Revision
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$54.58+4.8%$4.52 billionN/A0.00Analyst Report
Increase in Short Interest
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$75.67+4.9%$4.42 billion$6.87 million-7.31Analyst Report
Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.19+1.5%$4.25 billion$204.89 million-36.49
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.64+1.8%$4.08 billion$806.43 million-9.58Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$74.47+2.3%$3.97 billion$1.11 billion23.95Analyst Report
I-Mab logo
IMAB
I-Mab
1.4$55.09+9.9%$3.96 billion$4.31 million-1.91Increase in Short Interest
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$75.90+1.4%$3.72 billionN/A-21.62Analyst Report
High Trading Volume
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$53.36+2.4%$3.71 billion$117.91 million-10.82
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$44.48+5.0%$3.58 billionN/A-5.99
LEGN
Legend Biotech
1.2$26.76+1.1%$3.53 billion$64.39 million0.00Decrease in Short Interest
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.14+2.4%$3.49 billion$114.62 million-7.72Analyst Report
Insmed logo
INSM
Insmed
1.2$33.02+4.1%$3.41 billion$136.47 million-12.70
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.28+3.2%$3.41 billion$339.08 million-12.37Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.90+1.2%$3.37 billion$306.98 million-6.85
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.34+0.3%$3.30 billion$36.13 million-70.66Unusual Options Activity
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$89.75+3.7%$3.25 billion$26.52 million-7.91
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$115.44+3.8%$3.12 billionN/A-57.43Insider Selling
News Coverage
Arvinas logo
ARVN
Arvinas
1.5$62.89+2.5%$3.07 billion$42.98 million-24.57
Alkermes logo
ALKS
Alkermes
1.2$19.23+1.9%$3.06 billion$1.17 billion-41.80
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$69.43+1.7%$3.05 billion$421.03 million24.45Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.3$22.69+1.5%$2.99 billion$80.43 million108.05Decrease in Short Interest
Gap Down
Viela Bio logo
VIE
Viela Bio
0.8$53.01+0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.21+1.9%$2.82 billion$901.90 million-23.36
Organogenesis logo
ORGO
Organogenesis
1.0$21.90+3.7%$2.80 billion$260.98 million-365.00
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.80+0.6%$2.79 billion$644.77 million-10.39
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.95+2.9%$2.69 billion$306.49 million25.79
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.53+3.4%$2.69 billionN/A-23.92
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.96+5.5%$2.65 billion$25 million-9.19Insider Selling
News Coverage
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.98+6.7%$2.64 billion$182.24 million-8.68Analyst Upgrade
Gap Down
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$32.27+3.8%$2.61 billion$60,000.00-10.02
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$41.47+3.1%$2.58 billion$2.11 million-8.98Analyst Report
News Coverage
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$151.03+2.7%$2.51 billion$120.28 million-152.56Analyst Report
Decrease in Short Interest
News Coverage
Xencor logo
XNCR
Xencor
1.0$43.17+6.9%$2.50 billion$156.70 million-30.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$59.80+4.5%$2.40 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.64+1.3%$2.36 billion$33.94 million-89.03
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.21+2.3%$2.35 billion$15 million-17.39Unusual Options Activity
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.81+0.5%$2.18 billion$963.01 million13.61
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$27.83+3.6%$2.12 billion$23.90 million-17.29Analyst Report
Analyst Revision
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.17+1.3%$2.01 billion$410,000.00-6.12Analyst Report
News Coverage
Amarin logo
AMRN
Amarin
1.6$5.11+0.6%$2.01 billion$429.76 million-102.18
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.55+3.4%$2.00 billionN/A-19.91
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.80+5.3%$1.98 billion$103.54 million-19.40Insider Selling
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$63.93+2.6%$1.96 billionN/A-27.20Increase in Short Interest
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$120.94+4.4%$1.94 billionN/A-10.93
Kura Oncology logo
KURA
Kura Oncology
1.6$29.20+5.8%$1.93 billionN/A-17.91
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$47.01+2.9%$1.93 billionN/A0.00Analyst Report
Insider Selling
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.65+1.7%$1.89 billion$34.51 million-17.65
MacroGenics logo
MGNX
MacroGenics
1.2$31.28+5.5%$1.88 billion$64.19 million-9.99Decrease in Short Interest
MORF
Morphic
1.3$55.98+3.0%$1.82 billion$16.98 million-35.88Insider Selling
Decrease in Short Interest
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.